Stocks / Alpha Vantage News Sentiment

Moderna Stock Drops After Morgan Stanley Sticks To Neutral Rating Despite Lifting Price Target

Moderna (MRNA) stock fell 7% despite Morgan Stanley raising its price target to $39, up from $33, while maintaining an "equal-weight" (neutral) rating. The market reacted more to the cautious tone of the analyst's report than the increased price target. Morgan Stanley highlighted vaccines and a new cancer therapy as future growth drivers, following a solid Q1 earnings report from Moderna.